Milestone Pharmaceuticals Inc.
NASDAQ:MISTBiotechnology
-$0.00 today
- Market cap
- $57.32M
- Beta
- 0.96
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$0.52
Volume 2.23M
Average 1.99M
Returns on capital
Milestone Pharmaceuticals Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-151.0%
avg -107.3%
ROIC
-62.0%
avg -53.7%
ROA
-55.5%
avg -48.6%
Analysis
ROA is currently the strongest return metric at -55.5% versus its period average of -48.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Joseph G. Oliveto | Chief Executive Officer, President & Director | USD 931.38K | 58 | — | — |
David Bharucha FACC | Chief Medical Officer | USD 664.42K | 64 | — | — |
Amit Hasija | Chief Financial Officer & Executive Vice President of Corporate Development | USD 631.86K | 53 | 204.00K | 0.24% |
Guy Rousseau | SVP of Regulatory Affairs and Quality Management | — | — | — | — |
Philippe Douville | Founder, Strategic Advisor & Member of Scientific Advisory Board | — | 64 | 0 | <0.01% |
Philip T. Sager FACC FAHA FHRS | Chief Medical Advisor & Member of the Scientific Advisory Board | — | 70 | — | — |
Jeff Moore | Vice President of Sales | — | — | — | — |
Jeff Nelson | Chief Operating Officer | — | 45 | — | — |
Roshan Girglani | Vice President of Marketing | — | — | — | — |
David Sandoval | General Counsel & Chief Compliance Officer | — | 48 | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Feb 2, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
13
$1.18M
Net Transaction Value
−$1.18M
Net selling
Most Active
Oliveto Joseph
5 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Apr 16, 26Apr 16, 2026 | Oliveto Joseph Direct | Sell | $82.5K$82,490.00 |
| Jan 26, 26Jan 26, 2026 | Bharucha David Direct | Sell | $23.6K$23,632.85 |
| Jan 26, 26Jan 26, 2026 | Muller Lorenz Direct | Sell | $21.6K$21,577.40 |
| Jan 26, 26Jan 26, 2026 | Hasija Amit Direct | Sell | $23.6K$23,632.85 |
| Jan 26, 26Jan 26, 2026 | Oliveto Joseph Direct | Sell | $66.6K$66,629.39 |
| Jan 26, 26Jan 26, 2026 | Nelson Jeffrey Edward Direct | Sell | $23.6K$23,632.85 |
| Jan 8, 26Jan 8, 2026 | Oliveto Joseph Direct | Sell | $96.8K$96,750.00 |
| Jan 7, 26Jan 7, 2026 | Oliveto Joseph Direct | Sell | $1.1K$1,125.00 |
| Dec 15, 25Dec 15, 2025 | Nelson Jeffrey Edward Direct | Sell | $134.6K$134,576.24 |
| Dec 15, 25Dec 15, 2025 | Bharucha David Direct | Sell | $134.6K$134,576.24 |
1–10 of 13
Summary
Insiders reported 0 buys worth $0.00 and 13 sells worth $1.18M over the last 12 months. That adds up to net selling of $1.18M. Oliveto Joseph was the most active insider with 5 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -32.4% | +149.2% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at -32.4% over three years. Forward estimates point to Revenue at +149.2% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Milestone Pharmaceuticals Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about MIST's management, answered from reported figures.
Who manages MIST?
Milestone Pharmaceuticals Inc. (MIST) lists 10 active executives. The top listed executive is David Bharucha FACC, Chief Medical Officer.
Are MIST insiders buying or selling?
Recent insider activity shows net buying of $27.55M.
Continue the stock analysis
Jump to another research area for this company.